| Old Articles: <Older 6311-6320 Newer> |
|---|
 |
HHMI Bulletin
May 2010 |
Lummis Elected HHMI Trustee Fred R. Lummis, a Houston businessman and entrepreneur, has been elected a Trustee of HHMI. He becomes one of 11 Trustees of the Institute.   |
HHMI Bulletin
May 2010 |
Jibrell Selected as Vice President of Information Technology Mohamoud Jibrell, an expert in global information technology (IT), has been named HHMI's next Vice President of Information Technology. |
The Motley Fool
May 4, 2010
Brian Orelli |
Earnings Growth Trumps Revenue Growth, Except Here A solid quarter for Pfizer, but is there more in the tank? |
The Motley Fool
May 3, 2010
Brian Orelli |
While You Were Reveling in Dendreon's Win The FDA has approved Vimovo, an arthritis drug from Pozen and AstraZeneca, and Bristol-Myers Squibb also got a decision from the FDA, but it wasn't the positive kind. |
Chemistry World
May 2010
Derek Lowe |
Column: In the pipeline The author wonders whether tagging molecules with fluorescent labels for assay is like tracking the members of a shoal of fish by tying each one to a whale. In the pharmaceutical business, our work absolutely lives and dies by assay results. |
BusinessWeek
April 30, 2010
Drew Armstrong |
The Lobbying for Death by Diabetes How a health-reform provision may help spur sales of insulin. |
The Motley Fool
April 30, 2010
Brian Orelli |
Living the Blockbuster Model AstraZeneca's top drugs provide top-line growth in the first quarter. |
The Motley Fool
April 30, 2010
Brian Orelli |
Pricey Provenge Pumps Up Dendreon Dendreon's prostate cancer drug is approved, but at what cost, and will insurance pay for it? |
The Motley Fool
April 30, 2010
Brian Orelli |
New CEO, Same Old Double-Digit Increases Another strong quarter from Celgene. |
The Motley Fool
April 29, 2010
Brian Orelli |
A Prescription to Investigate Further Let's not worry just yet about Medco's margins. |
| <Older 6311-6320 Newer> Return to current articles. |
